Harvard-linked immunotherapy developer T-Scan Therapeutics will be helmed by serial biotech entrepreneur Christoph Westphal, who has previously achieved multiple exits.
Harvard University has launched US-based company T-Scan Therapeutics to drive research into immunotherapies for cancer, FierceBiotech reported today.
The report cited an April 23 corporate filing naming T-Scan’s chief executive as Christoph Westphal, previously head of neuromuscular drug developer Flex Pharma, which went public for $86.4m in 2015.
Generally, immunotherapies for cancer aim to train the patient’s immune system to fight the disease by reengineering fighter cells such as T-cells to recognise and destroy cancerous intruders.
…
